



Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

November 22, 2022

ENCINITAS, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that Company executives will provide a company overview during fireside chats at the following upcoming investor conferences:

- **Event: 5th Annual Evercore ISI HealthCONx Conference**

Location: Virtual

Date: Tuesday, November 29, 2022

Time: 1:00-1:20 PM ET

- **Event: Piper Sandler 34th Annual Healthcare Conference**

Location: New York, NY

Date: Thursday, December 1, 2022

Time: 9:30-9:55 AM ET

Members of the Ventyx management team will also host investor meetings during the conferences.

Webcasts of the presentations will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of each event for thirty days.

About Ventyx Biosciences

Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes three clinical-stage internally discovered programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit www.ventyxbio.com.

Investor Relations Contact

Patti Bank

Managing Director

ICR Westwicke

(415) 513-1284

IR@ventyxbio.com